David E. Mire, Ph.D, MBA
Mansfield,USA
Summary
- Accomplished medical leader with a proven record of advancing clinical excellence and operational efficiency.
- Skilled in strategic planning, regulatory compliance, and patient-centered care.
- Experienced in building collaborative, high-performing teams to meet changing healthcare demands.
- Recognized for implementing evidence-based solutions that improve patient outcomes and streamline operations.
- Dedicated to continuous improvement and innovation in healthcare.
Overview
2027
2027
years of professional experience
Work History
Senior Director, Medical Content Strategy
NPG Health
Morristown, NJ
10.2023 - Current
- Oversee medical and scientific initiatives to facilitate clients' efforts to deliver innovative drugs and gene therapies for rare diseases.
- Lead cross-functional medical and scientific initiatives supporting marketing, creative, and project management objectives. Ensure scientific activities align with marketing strategies and creative content.
- Serve as the primary medical liaison, ensuring effective collaboration and information exchange between client organizations and internal leadership.
Field Medical Director, Southwest
Calliditas Therapeutics AB
2022 - 2023
- Established ongoing partnerships with healthcare key opinion leaders (KOLs) across Texas, Oklahoma, New Mexico, and Arizona to deliver comprehensive medical and scientific education for Calliditas.
- Established and nurtured essential relationships with key stakeholders at MD Anderson Cancer Center, Baylor College of Medicine, and UTMB to enhance collaborative efforts.
- Engaged with key leaders at MD Anderson Cancer Center, Baylor College of Medicine, and UTMB to strengthen collaboration and promote support for Calliditas initiatives.
- Delivered comprehensive training on IgA nephropathy and its exclusive medication to nephrology fellows, enhancing clinical application skills.
- Oversaw medical affairs initiatives, ensuring alignment with corporate objectives and compliance standards.
- Spearheaded key opinion leader engagement to support product positioning in the market.
Director, Field Medical Affairs, Gastroenterology Division
Takeda Pharmaceuticals America, Inc.
Deerfield, Illinois
01.2019 - 01.2022
- Led a team of seven MSLs with nationwide coverage supporting Gattex (teduglutide) for Short Bowel Syndrome. Managed the team in a virtual setting since early 2020 due to COVID-19 pandemic.
- Highlighted major contributions to team success
- Conducted interviews and recruited team members to build a skilled and effective MSL team
- Managed comprehensive training programs for team members
- Monitored and managed MSL team expenses to maintain budgetary compliance
- Work closely with Medical Unit ensuring coordination
Executive Medical Science Liaison, Gastroenterology Division
Takeda Pharmaceuticals America, Inc.
01.2017 - 01.2019
- Responsible for developing ongoing professional relationships with national, regional, and local healthcare key opinion leaders (KOLs) to provide medical and scientific support/education for Takeda in Texas, Oklahoma and New Mexico
- Outlined key activities for team projects
- Provide medical and clinical support for Entyvio (vedolizumab) for the treatment of IBD (Crohn’s disease and Ulcerative Colitis)
- Sought opportunities for investigator-initiated trials
- Served as clinical trial liaison for company-sponsored studies to facilitate collaboration and support trial execution
Senior Medical Science Liaison, Renal Division
OPKO Health, Inc.
Miami, Florida
01.2016 - 01.2017
- Developed ongoing professional relationships with national, regional, and local healthcare key opinion leaders (KOLs) to provide medical and scientific support for OPKO Renal in the South-central US.
- Provided medical and clinical support for launch of newly approved prohormone used to treat secondary hyperparathyroidism (SHPT) in chronic kidney disease patients
- Identified Investigator Initiated Trial Opportunities
- Initiated and led MSL office hours, an ongoing training initiative in support of field sales force
- Initiated and led MSL office hours to enhance training and support for field sales force
- Developed educational materials and targeting tools to facilitate MSL deployment in new market
- Identified opportunities for Investigator Initiated Trials to advance research and collaboration
Medical Science Liaison, Medical Affairs
inVentiv Health/Endo Pharmaceuticals
Somerset, New Jersey
01.2016 - 01.2016
- Responsible for developing ongoing professional relationships with national, regional and local healthcare key opinion leaders (KOLs) to provide medical and scientific support/education for Endo Pharmaceutical initiatives in orthopedic medicine and urology (Peyronie’s disease, Dupuytren’s Contracture)
- Key Accomplishments
- Delivered ongoing education to healthcare providers (MD, RN) on Endo areas of disease focus and collaborated with key clinicians to develop publications
- Identify Investigator Initiated Trial Opportunities
- Contributed to development of evidence-based medicine platform to support Endo Pharmaceutical initiatives
Director, Scientific Communications, Strategic Development
Smith & Nephew
Fort Worth, Texas
01.2014 - 01.2016
- Created and enhanced global strategic scientific platforms for the Advanced Wound Management division. Oversee traditional and internet based Medical Education initiatives.
- Provided scientific support for corporate debridement strategy, aligning efforts with drug and device franchise goals to strengthen market positioning.
- Oversaw the planning and coordination of scientific publications.
- Managed trials initiated by investigators to ensure compliance and quality.
- Created evidence-based medicine platform to underpin Smith & Nephew initiatives, ensuring alignment with best practices and industry standards.
Director, Medical Science, Medical and Clinical Affairs
Smith & Nephew
01.2011 - 01.2014
- Oversaw MSL team execution and development as well as creation of all MSL materials (presentations, etc.) Worked with advertising review committee to gain approval of all MSL field-based materials Maintained and disseminated the highest level of medical and scientific knowledge relevant to Smith & Nephew Biotherapeutics' vision and marketed products throughout the organization.
- Key Accomplishments
- Developed scientific basis for innovative marketing approach to collagenase debridement, enhancing product positioning and outreach.
- Identified and developed scientific basis for new marketing approach to collagenase debridement
- Delivered national and regional MSL coverage
- Provided comprehensive medical and scientific support for Regranex (becaplermin gel) across multiple functions, facilitating informed decision-making and strategic initiatives.
- Executive Leadership
- Medical and Clinical Affairs
Associate Director, Marketing
Smith & Nephew
01.2008 - 01.2011
- Led all marketing activities related to Collagenase SANTYL Ointment, including positioning and message development, creative concept development and testing, speaker training planning, implementation and advocacy development, publication review, development of long-term strategic plan, coordination of commercial activities with clinical development group, and sales force training.
- Key Accomplishments
- Led brand team which drove revenue growth from $13MM to more than $140MM over 3 year period, creating the largest prescription product in the history of wound care . Re-invigorated 45 year old brand with a modern market research based campaign fully grounded and supported by scientific and clinical rationale
- Launched marketing campaign supporting first randomized, controlled trial of SANTYL Ointment in over 30 years
- Developed innovative sales collateral, integrating print and electronic assets to enhance communication and support sales efforts.
Product Manager, Marketing - Medical Strategy (Diabetes/Metabolic) Marketing and Commercial Operations
Daiichi Sankyo, Inc.
Parsippany, New Jersey
01.2007 - 01.2008
- Planned, developed and executed brand marketing activities focused on medical marketing initiatives including medical education program planning, key opinion leader/advocacy development, phase IV program development, publication planning, and brand lifecycle management for Welchol (colesevelam HCl) type 2 diabetes indication.
- Coordinated brand activities with marketing research, market planning, and clinical development to align strategic initiatives.
- Highlighted significant achievements in role.
- Coordinated development of mechanism of action pre-clinical and clinical studies
- Developed innovative marketing concepts for campaigns. and testing
- Formulated strategy for professional education initiatives.
- Speaker training planning and implementation
- National and regional advisory board planning and implementation
- Positioning and message development
Manager, New Product Planning
Daiichi Sankyo, Inc.
01.2004 - 01.2007
- Planned and implemented key market development strategies including product branding, publications planning, advocacy development and medical education from phase II to NDA filing for type 2 diabetes indication for Managed WelChol development.
- Provided recommendations to Senior Commercial and Research management committees
- Recommended strategies to Senior Commercial and Research management committees to guide product development decisions
- Documented significant achievements
- Managed development of rivoglitazone
- Assessed phase 3 project viability
- U.S. NPV and Forecast development
- Developed international brand identity
- Managed multiple outside vendor projects for objection handling and managed care market research/reimbursement strategy
- Conducted primary and secondary market research to determine market needs and opportunities for new indications and developed sales forecasts
- Planned, developed, and executed national and regional advisory boards to gather insights and inform product strategies
- Managed outside vendor projects for objection handling and developed managed care market research/reimbursement strategies to enhance market access
- Researched re-branding opportunities for type 2 diabetes indication
- Represented U.S. commercial interests on integrated development teams (clinical development, Tokyo R&D).
- Key Accomplishments
- Rivoglitazone
- WelChol (colesevelam HCl)
Medical Science Liaison, Medical and Scientific Affairs
Daiichi Sankyo, Inc.
01.2001 - 01.2004
- Provided MSL coverage for the Southwest US (Dallas-Fort Worth, Oklahoma City, Albuquerque, Phoenix).
- Developed ongoing professional relationships with national, regional and local healthcare key opinion leaders (KOLs) to provide medical and scientific support for Sankyo Pharma Inc. initiatives in cardiovascular medicine and diabetes.
- Educated national, regional and local healthcare providers and colleagues on new therapies developed and commercialized by Sankyo Pharma Inc., enhancing their understanding and application of these treatments.
- Key Accomplishments
- Assisted in securing managed care coverage of multiple products (Benicar, WelChol, GlucoWatch G2 Biographer) for over 30 million patient lives
- Provided scientific input to Benicar marketing team in the development of new product marketing strategies
- Designed and developed the structure-activity/pharmacology explanation of Benicar efficacy.
- Abstract/poster presentation at the 2004 American Society of Hypertension Annual Scientific Meeting and manuscript publication in the Journal of Cardiovascular Pharmacology
- Designed and implemented CD-ROM based advanced training courses in heart failure and diabetic nephropathy, equipping the field sales force with critical knowledge for effective product promotion.
Post-Doctoral Research Fellow
National Cancer Institute, National Institutes of Health
Frederick, Maryland
01.1999 - 01.2001
- Designed and developed multi-step syntheses which produced novel site selective prodrugs for use as inactivators of a human DNA repair protein
- Developed novel medicinal agents for use in treatment of CNS neoplasms
- Showcased major contributions to medicinal chemistry initiatives
- Determined enzyme kinetics data for prodrug cleavage, contributing to understanding drug activation in therapeutic applications
- Investigated pharmacologically important parameters of compounds to assess potential efficacy and safety in clinical settings.
Process Chemist
Merck & Co., Inc.
Albany, Georgia
01.1998 - 01.1998
- Developed improved purification method for key intermediate in Cozaar (losartan potassium) production, enhancing overall process efficiency
- Synthesized important targets for engineering teams in Cozaar (losartan potassium) and Zocor (simvastatin) production
- Synthesized targeted compounds for engineering teams in Cozaar (losartan potassium) and Zocor (simvastatin) production, supporting project timelines and objectives
- Key Accomplishments
Education
MBA - Corporate Entrepreneurship
Lehigh University
Bethlehem, Pennsylvania01-2008
Research Fellow - Medicinal Chemistry
National Cancer Institute
Frederick, Maryland01-2001
Ph.D. - Organic Chemistry
The University of Texas
Arlington, Texas01-1999
B.S. - Chemistry
Texas A&M University
College Station, Texas01-1992
Skills
- Extensive experience in pharmaceutical scientific and commercialization activities across a range of functions
- Demonstrated ability to integrate key marketing, scientific, clinical and financial objectives into a cohesive strategic vision
- Coordination of marketing with medical and clinical affairs to bring products to market in a scientifically credible manner
- Managed and implemented key marketing strategies in preparation for launch and post-launch activities via traditional and digital marketing techniques
- New Product Planning and Business Development
Accomplishments
- Supervised multiple medical and marketing teams across several companies.
- Co-author of “A Review of the Structural and Functional Features of Olmesartan Medoxomil, an Angiotensin Receptor Blocker,” published in Journal of Cardiovascular Pharmacology in 2005. This paper served as the basis for a new, global BENICAR marketing campaign.
- Achieved record SANTYL growth ($10MM to $140MM over 3 year period) through effectively applying detailed scientific knowledge create a modern marketing approach.
Timeline
Senior Director, Medical Content Strategy
NPG Health
10.2023 - Current
Director, Field Medical Affairs, Gastroenterology Division
Takeda Pharmaceuticals America, Inc.
01.2019 - 01.2022
Executive Medical Science Liaison, Gastroenterology Division
Takeda Pharmaceuticals America, Inc.
01.2017 - 01.2019
Senior Medical Science Liaison, Renal Division
OPKO Health, Inc.
01.2016 - 01.2017
Medical Science Liaison, Medical Affairs
inVentiv Health/Endo Pharmaceuticals
01.2016 - 01.2016
Director, Scientific Communications, Strategic Development
Smith & Nephew
01.2014 - 01.2016
Director, Medical Science, Medical and Clinical Affairs
Smith & Nephew
01.2011 - 01.2014
Associate Director, Marketing
Smith & Nephew
01.2008 - 01.2011
Product Manager, Marketing - Medical Strategy (Diabetes/Metabolic) Marketing and Commercial Operations
Daiichi Sankyo, Inc.
01.2007 - 01.2008
Manager, New Product Planning
Daiichi Sankyo, Inc.
01.2004 - 01.2007
Medical Science Liaison, Medical and Scientific Affairs
Daiichi Sankyo, Inc.
01.2001 - 01.2004
Post-Doctoral Research Fellow
National Cancer Institute, National Institutes of Health
01.1999 - 01.2001
Process Chemist
Merck & Co., Inc.
01.1998 - 01.1998
Research Fellow - Medicinal Chemistry
National Cancer Institute
Ph.D. - Organic Chemistry
The University of Texas
B.S. - Chemistry
Texas A&M University
Field Medical Director, Southwest
Calliditas Therapeutics AB
2022 - 2023
MBA - Corporate Entrepreneurship
Lehigh University
PUBLICATIONS
- “A Review of the Structural and Functional Features of Olmesartan Medoxomil, an Angiotensin Receptor Blocker”, David E. Mire, Ph.D., Tonous N. Silfani, Ph.D., Michael K. Pugsley, Ph.D. Journal of Cardiovascular Pharmacology, 2005 Nov;46(5):585-93
- “The Dose-Dependent Antihypertensive Actions of Olmesartan Medoxomil, an Angiotensin II (AT-II) Receptor Blocker”, Michael K. Pugsley, Ph.D., David E. Mire, Ph.D., Tonous N. Silfani, Ph.D., Sandeep Gupta, Ph.D. American Journal of Hypertension, 2004; 17(5) Part 2, 121A.
- “Palladium Catalyzed Synthesis of Polyaniline and Related Polymers”, David E. Mire. Ph.D. Dissertation, The University of Texas, Arlington, Texas, 1999.
- “Synthesis of Polyaniline via Palladium Catalysis”, Martin Pomerantz, Ph.D. and David E. Mire, Ph.D. Polymer Preprints, American Chemical Society, Division of Polymer Chemistry, 1998, 39(1), 128
- “Effect of Clostridial Collagenase Ointment on Healing, Scarring, and Granulation Tissue in Acute Wounds” David E. Mire, Ph.D., Shai M. Rozen, MD, Kathy Weedon, BS, Herbert Slade, MD FAAAI, American Association for the Advancement of Wound Care, Las Vegas, NV, September 2013.
- “The Dose-Dependent Antihypertensive Actions of Olmesartan Medoxomil, an Angiotensin II (AT-II) Receptor Blocker”, Michael K. Pugsley, Ph.D., David E. Mire, Ph.D., Tonous N. Silfani, Ph.D., Sandeep Gupta, Ph.D. American Society of Hypertension Scientific Sessions, New York, NY, May 2004.
- “Palladium Catalyzed Synthesis of Polyaniline”, Martin Pomerantz, Ph.D. and David E. Mire, Ph.D., International Conference on Science and Technology of Synthetic Metals (ICSM '98), Montpellier, France, July, 1998.
- “Synthesis of Polyaniline via Palladium Catalysis”, Martin Pomerantz, Ph.D. and David E. Mire, Ph.D., 215th National Meeting of the American Chemical Society, Dallas, Texas, March/April, 1998.
- “Synthesis of Highly Ordered, Defect Free Polyaniline”, Martin Pomerantz, Ph.D. and David E. Mire, Ph.D., 30th Annual Meeting-in-Miniature of the Dallas-Fort Worth Section of The American Chemical Society, Fort Worth, Texas, April, 1997.
MILITARY EXPERIENCE, UNITED STATES MARINE CORPS
- Corporal, Headquarters Battery, 10th Marines, 2nd Marine Division, FMF 1984-1988
- Supervisor, Communications Repair – HQ Battery, 10th Marines, 2nd Marine Division, FMF
- Communications Repair – Communications Platoon, 4th Battalion, 10th Marines, 2nd Marine Division, FMF
- Formally trained as a Ground Radio Technician, MCCES, 29 Palms, CA
- Other duties as required as a Corporal of Marines
- Awarded Meritorious Mast by the Inspector General of the U.S. Marine Corps